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Contributions of physicians to government-
subsidised disease prevention programmes:  
an appeal for active participation
Pneumococcal infection, particularly invasive 
pneumococcal disease (IPD), has placed a substantial 
global burden of disease.1 In Hong Kong, from 2007 
to 2015, the incidence rate of IPD increased from 
1.7 to 2.9 per 100 000 population.2 It is one of the 
leading causes of disability and mortality, affecting 
individuals aged ≥65 years who are at higher risk 
of complications and premature death.3 The total 
number of local residents aged ≥65 years has already 
exceeded one million, accounting for approximately 
16% of the whole population in Hong Kong.4 Due 
to the ageing population, the incidence of IPD is 
expected to rise continuously in the coming years.5
 Evidence has shown that pneumococcal 
immunisation can effectively decrease the incidence 
and mortality of pneumococcal infection and 
IPD among older adults.6,7 An earlier large-scale 
cohort study demonstrated that immunisation was 
associated with a significant decrease in the risk 
of pneumococcal infection (hazard ratio=0.56) 
among patients aged >65 years.8 The pneumococcal 
immunisation can also lower the risks of both 
myocardial infarction9 and ischaemic stroke.10 
Although pneumococcal immunisation is beneficial 
for IPD and cardiovascular disease control, the 
programme participation remained suboptimal 
worldwide.
 The uptake rate of pneumococcal immunisation 
among older adults was only around 61% in the 
United States during 2013 to 2014.11 In England, 
the pneumococcal immunisation coverage among 
older adults was <70% during 2014 to 2015.12 In 
Hong Kong, only one-third of people aged ≥65 years 
received pneumococcal immunisation.13
 The Hong Kong SAR Government has launched 
two pneumococcal immunisation programmes to 
eligible residents in October 2019: the Vaccination 
Subsidy Scheme and the Government Vaccination 
Programme.14 The Vaccination Subsidy Scheme 
provided a subsidy of HK$210 (~US$27) and 
HK$250 (~US$32) for influenza and pneumococcal 
immunisation, respectively, to eligible older 
individuals at enrolled private clinics as a measure 
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to strengthen the preventive strategy for these 
diseases. It offers subsidies for both the 13-valent 
pneumococcal conjugate vaccine and the 23-valent 
polysaccharide pneumococcal vaccine. The 
Government Vaccination Programme provides 
eligible individuals with free pneumococcal 
immunisation at residential care homes for the 
elderly, designated centres of the Department of 
Health, and public clinics or hospitals managed by 
the Hospital Authority.14 
 In addition to pneumococcal vaccine, human 
papillomavirus (HPV) vaccination is currently 
available under the Hong Kong Childhood 
Immunisation Programme, wherein eligible 
female students may receive two doses of 9-valent 
HPV vaccine in their primary five and six school 
years.15 Other examples of Government-subsidised 
programmes for disease prevention include cervical 
cancer screening,16 colorectal cancer screening,17 
and the Smoking Cessation Programme.18
 In this issue of the Hong Kong Medical Journal, 
Man et al19 report an 8-year large-scale retrospective 
cohort study that included 792 adult patients in a 
major hospital. The authors found that the 30-day 
mortality rates were 11.5% overall and 24.5% in 
those patients with IPD. Among 170 patients 
admitted to the intensive care unit, the in-hospital 
mortality was 31.2%. The study results indicate that 
older age, the presence of chronic kidney disease, 
and disease severity are significantly associated 
with 30-day mortality. The study is limited by the 
absence of controls for potential confounders 
and its retrospective single-centre design; thus 
the generalisability to other settings may require 
cautious interpretation. This necessitates future 
evaluations to explore drug resistance patterns and 
capsular serotypes of pneumococcus. As claimed 
by the authors, this was the first and largest-scale 
investigation on pneumococcal disease in Hong 
Kong showing the significant burden posed 
by pneumococcal infection. The study exerts a 
significant impact on clinical care and resource 
planning for hospitals, given that up to 33% of IPD 
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patients require intensive care unit care. In view of 
the public health impact, the role of pneumococcal 
vaccination in prevention should be enhanced.
 Substantial evidence supports the effectiveness 
of preventive care and disease screening. A meta-
analysis of 26 randomised controlled trials consisting 
of >73 000 individuals found that HPV immunisation 
can effectively protect adolescent girls and young 
females from cervical cancer.20 An international 
study conducted in eight countries by the World 
Health Organization found that the cumulative 
incidence of cervical cancer decreased by 94%, 93%, 
91%, 84%, and 64% for a screening interval of 1 year, 
2 years, 3 years, 5 years, and 10 years, respectively, 
among women who were screened before age 
35 years.21 Screening is also beneficial for women aged 
61 to 65 years, and is associated with a decreased risk 
of cervical cancer (hazard ratio=0.42), contributing 
to a reduction of approximately 3.3 cancer cases 
per 1000 women.22 Screening by faecal occult blood 
test and colonoscopy can effectively reduce the risk 
of colorectal cancer–related death by 33%23 and 
68%24, respectively. Among patients who smoke 
≥15 cigarettes daily, smoking reduction by 50% can 
significantly reduce the risk of lung cancer.25
 The effect of physician intervention on disease 
prevention and screening is well documented in 
the literature. Participation rates of pneumococcal 
vaccination are associated with physician-delivered 
routine vaccine and promotion programmes.26 A 
study among Japanese primary care physicians 
found that patients who had pneumococcal 
vaccination were more likely to have received advice 
from physicians than those who did not receive 
such advice (80% vs 21%), and a strong association 
was shown between physician recommendation and 
patient participation in vaccination with an adjusted 
odds ratio of 8.50.27 A study in France demonstrated 
that patients who received recommendations 
from trusted family physicians were more likely 
to participate in HPV vaccination programme.28 
In Hungary, physicians effectively motivated 
approximately 27% of women who initially refused 
to join cervical cancer screening programmes.29 
Moreover, higher non-compliance rates were related 
to family physicians being foreign, at a younger 
age, and with a longer distance to the clinic from 
the patient’s home.30 A population-based telephone 
survey in Hong Kong found that people who were 
recommended by physicians were 23.5-fold more 
likely to have colorectal cancer screening uptake 
than those who did not.31 A recent study conducted 
in Canada using large administrative databases 
highlighted that the uptake of colorectal cancer tests 
by family physicians was significantly associated with 
greater uptake by their patients.32 Another study 
found that clinicians who specialised in respiratory 
diseases, thoracic surgery, and cardiology were more 
committed to encouraging patients to cease tobacco 
use.33
 We believe that the study by Man et al19 acts 
as a call for more active participation by physicians 
in disease prevention and screening programmes, 
and appeal for your support. Physicians play an 
important role in both primary and secondary 
disease prevention for asymptomatic individuals, 
including promotion of lifestyle modifications, 
vaccination for infectious diseases, and screening 
for early-stage cancer lesions such as cervical cancer 
and colorectal cancer.
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